CD8A and cancer: To showcase how ExoGAN may accelerate precision cancer immunotherapy, we leveraged antigen-presenting cell-derived EVs (APC-EVs), antigen cell-derived nanoparticles that carry MHC-I, and co-stimulatory factors that enable neoantigen delivery to CD8+ T cells.